Literature DB >> 22295310

Perioperative risk analysis for acute respiratory distress syndrome after elective oesophagectomy.

Diana J Paul1, Glyn G Jamieson, David I Watson, Peter G Devitt, Philip A Game.   

Abstract

BACKGROUND: Acute respiratory distress syndrome (ARDS) is a major contributor to respiratory morbidity and mortality after oesophagectomy. Several pre-, intra- and post-operative factors are thought to predispose to its development in the post-oesophagectomy period. The aim of this study was to determine factors predisposing to ARDS in the post-oesophagectomy period.
METHODS: A total of 112 patients who underwent elective oesophagectomy for oesophageal cancer (gastro-oesophageal adenocarcinoma and high-grade dysplasia, 93; oesophageal squamous cell carcinoma, 16; oesophageal oat cell tumour, 1; oesophageal anaplastic carcinoma, 1; oesophageal colloid carcinoma, 1) between 1 January 2003 and 31 December 2006 formed the study group in this retrospective study. The pre-, intra and post-operative data for these patients (male : female = 89:23, mean age 60.8 years) were collected from an oesophagectomy database and hospital medical records.
RESULTS: The incidence of ARDS was 13%. The in-hospital mortality among ARDS cases was 20% and 1-year mortality was 40%. Various factors such as preoperative chronic respiratory disease (P-value = 0.000, odds ratio = 17.76), smoking pack-years (P-value = 0.045, odds ratio = 1.02), abnormal preoperative forced expiratory volume in 1 s (P-value = 0.009, odds ratio = 7.97), high percentage of oxygen in inspired air (P-value = 0.041, odds ratio = 1.24) and use of perioperative inotropes (P-value = 0.021, odds ratio = 4.26) were associated with ARDS.
CONCLUSIONS: Preoperative physiological status as indicated by a preoperative history of chronic respiratory disease and preoperative pulmonary function influenced the post-operative outcome in our patients. The use of perioperative inotropes suggests perioperative cardiorespiratory instability, and could also predispose to the development of ARDS in the post-operative period.

Entities:  

Mesh:

Year:  2011        PMID: 22295310     DOI: 10.1111/j.1445-2197.2010.05598.x

Source DB:  PubMed          Journal:  ANZ J Surg        ISSN: 1445-1433            Impact factor:   1.872


  12 in total

1.  Risk factors for pulmonary complications after esophagectomy for esophageal cancer.

Authors:  Naoya Yoshida; Masayuki Watanabe; Yoshifumi Baba; Shiro Iwagami; Takatsugu Ishimoto; Masaaki Iwatsuki; Yasuo Sakamoto; Yuji Miyamoto; Nobuyuki Ozaki; Hideo Baba
Journal:  Surg Today       Date:  2013-04-14       Impact factor: 2.549

2.  Risk factors for pulmonary morbidities after minimally invasive esophagectomy for esophageal cancer.

Authors:  Tomoyuki Uchihara; Naoya Yoshida; Yoshifumi Baba; Taisuke Yagi; Tasuku Toihata; Eri Oda; Daisuke Kuroda; Tsugio Eto; Mayuko Ohuchi; Kenichi Nakamura; Hiroshi Sawayama; Koichi Kinoshita; Masaaki Iwatsuki; Takatsugu Ishimoto; Yasuo Sakamoto; Hideo Baba
Journal:  Surg Endosc       Date:  2017-12-22       Impact factor: 4.584

3.  Esophageal Position Affects Short-Term Outcomes After Minimally Invasive Esophagectomy: A Retrospective Multicenter Study.

Authors:  Tomoyuki Uchihara; Naoya Yoshida; Yoshifumi Baba; Yuichiro Nakashima; Yasue Kimura; Hiroshi Saeki; Shinsuke Takeno; Noriaki Sadanaga; Masahiko Ikebe; Masaru Morita; Yasushi Toh; Atsushi Nanashima; Yoshihiko Maehara; Hideo Baba
Journal:  World J Surg       Date:  2020-03       Impact factor: 3.352

4.  Preoperative Smoking Cessation is Integral to the Prevention of Postoperative Morbidities in Minimally Invasive Esophagectomy.

Authors:  Naoya Yoshida; Kenichi Nakamura; Daisuke Kuroda; Yoshifumi Baba; Yuji Miyamoto; Masaaki Iwatsuki; Yukiharu Hiyoshi; Takatsugu Ishimoto; Yu Imamura; Masayuki Watanabe; Hideo Baba
Journal:  World J Surg       Date:  2018-09       Impact factor: 3.352

5.  Predictors and outcomes of acute respiratory failure in hospitalised patients with acute pancreatitis.

Authors:  Mahesh Gajendran; Bharat Prakash; Abhilash Perisetti; Chandraprakash Umapathy; Vineet Gupta; Laura Collins; Prashanth Rawla; Priyadarshini Loganathan; Alok Dwivedi; Christopher Dodoo; Fortune Unegbu; Dan Schuller; Hemant Goyal; Shreyas Saligram
Journal:  Frontline Gastroenterol       Date:  2020-07-28

6.  Original scoring system for predicting postoperative morbidity after esophagectomy for esophageal cancer.

Authors:  Naoya Yoshida; Yoshifumi Baba; Masayuki Watanabe; Satoshi Ida; Takatsugu Ishimoto; Ryuichi Karashima; Shiro Iwagami; Yu Imamura; Yasuo Sakamoto; Yuji Miyamoto; Hideo Baba
Journal:  Surg Today       Date:  2014-07-06       Impact factor: 2.549

7.  Duration of Smoking Cessation and Postoperative Morbidity After Esophagectomy for Esophageal Cancer: How Long Should Patients Stop Smoking Before Surgery?

Authors:  Naoya Yoshida; Yoshifumi Baba; Yukiharu Hiyoshi; Hironobu Shigaki; Junji Kurashige; Yasuo Sakamoto; Yuji Miyamoto; Masaaki Iwatsuki; Takatsugu Ishimoto; Keisuke Kosumi; Hidetaka Sugihara; Kazuto Harada; Ryuma Tokunaga; Daisuke Izumi; Masayuki Watanabe; Hideo Baba
Journal:  World J Surg       Date:  2016-01       Impact factor: 3.352

8.  Extended thoracic lymph node dissection in robotic-assisted minimal invasive esophagectomy (RAMIE) for patients with superior mediastinal lymph node metastasis.

Authors:  Sylvia van der Horst; Michiel F G de Maat; Pieter C van der Sluis; Jelle P Ruurda; Richard van Hillegersberg
Journal:  Ann Cardiothorac Surg       Date:  2019-03

9.  The beta agonist lung injury trial prevention. A randomized controlled trial.

Authors:  Gavin D Perkins; Simon Gates; Daniel Park; Fang Gao; Chris Knox; Ben Holloway; Daniel F McAuley; James Ryan; Joseph Marzouk; Matthew W Cooke; Sarah E Lamb; David R Thickett
Journal:  Am J Respir Crit Care Med       Date:  2014-03-15       Impact factor: 21.405

10.  Double impact of cigarette smoke and mechanical ventilation on the alveolar epithelial type II cell.

Authors:  Jan Hirsch; Robert J Chalkley; Trevor Bentley; Alma L Burlingame; James A Frank
Journal:  Crit Care       Date:  2014-03-25       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.